Latest Bone Cancer News | Feature Articles, Bone Cancer Research

Bone Cancer News


Bone Cancer News

FDA_drug approval

Crysvita Approved for Treatment of Tumor-Induced Osteomalacia

The FDA has approved Crysvita® (burosumab-twza; Ultragenyx) for the treatment of fibroblast growth factor 23 (FGF23)-related hypophosphatemia in tumor-induced osteomalacia associated with phosphaturic mesenchymal tumors that cannot be curatively resected or localized in patients aged ≥2 years.